YPSOMED HOLDING AG CHF14.15 (REGD)YPSOMED HOLDING AG CHF14.15 (REGD)YPSOMED HOLDING AG CHF14.15 (REGD)

YPSOMED HOLDING AG CHF14.15 (REGD)

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.45 B‬CHF
‪78.37 M‬CHF
‪548.46 M‬CHF
‪3.63 M‬
Beta (1Y)
0.33
Employees (FY)
‪2.3 K‬
Change (1Y)
+318 +16.08%
Revenue / Employee (1Y)
‪238.88 K‬CHF
Net income / Employee (1Y)
‪34.13 K‬CHF

About YPSOMED HLDG


CEO
Simon Michel
Headquarters
Burgdorf
Founded
2003
ISIN
CH0019396990
FIGI
BBG00NRVXZN2
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003, and is headquartered in Burgdorf, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0QLQ is 326.5 CHF — it has decreased by −9.81% in the past 24 hours. Watch YPSOMED HOLDING AG CHF14.15 (REGD) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange YPSOMED HOLDING AG CHF14.15 (REGD) stocks are traded under the ticker 0QLQ.
0QLQ stock has fallen by −12.23% compared to the previous week, the month change is a −9.31% fall, over the last year YPSOMED HOLDING AG CHF14.15 (REGD) has showed a 8.83% increase.
We've gathered analysts' opinions on YPSOMED HOLDING AG CHF14.15 (REGD) future price: according to them, 0QLQ price has a max estimate of 495.00 CHF and a min estimate of 303.00 CHF. Watch 0QLQ chart and read a more detailed YPSOMED HOLDING AG CHF14.15 (REGD) stock forecast: see what analysts think of YPSOMED HOLDING AG CHF14.15 (REGD) and suggest that you do with its stocks.
0QLQ reached its all-time high on Sep 26, 2024 with the price of 438.5 CHF, and its all-time low was 103.0 CHF and was reached on Mar 16, 2020. View more price dynamics on 0QLQ chart.
See other stocks reaching their highest and lowest prices.
0QLQ stock is 29.52% volatile and has beta coefficient of 0.33. Track YPSOMED HOLDING AG CHF14.15 (REGD) stock price on the chart and check out the list of the most volatile stocks — is YPSOMED HOLDING AG CHF14.15 (REGD) there?
Today YPSOMED HOLDING AG CHF14.15 (REGD) has the market capitalization of ‪4.45 B‬, it has decreased by −1.48% over the last week.
Yes, you can track YPSOMED HOLDING AG CHF14.15 (REGD) financials in yearly and quarterly reports right on TradingView.
YPSOMED HOLDING AG CHF14.15 (REGD) is going to release the next earnings report on May 21, 2025. Keep track of upcoming events with our Earnings Calendar.
YPSOMED HOLDING AG CHF14.15 (REGD) revenue for the last half-year amounts to ‪324.00 M‬ CHF, despite the estimated figure of ‪298.65 M‬ CHF. In the next half-year revenue is expected to reach ‪349.20 M‬ CHF.
0QLQ net income for the last half-year is ‪32.60 M‬ CHF, while the previous report showed ‪41.79 M‬ CHF of net income which accounts for −21.99% change. Track more YPSOMED HOLDING AG CHF14.15 (REGD) financial stats to get the full picture.
Yes, 0QLQ dividends are paid annually. The last dividend per share was 2.00 CHF. As of today, Dividend Yield (TTM)% is 0.61%. Tracking YPSOMED HOLDING AG CHF14.15 (REGD) dividends might help you take more informed decisions.
YPSOMED HOLDING AG CHF14.15 (REGD) dividend yield was 0.55% in 2023, and payout ratio reached 34.83%. The year before the numbers were 0.68% and 34.02% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 21, 2024, the company has ‪2.30 K‬ employees. See our rating of the largest employees — is YPSOMED HOLDING AG CHF14.15 (REGD) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. YPSOMED HOLDING AG CHF14.15 (REGD) EBITDA is ‪178.76 M‬ CHF, and current EBITDA margin is 28.43%. See more stats in YPSOMED HOLDING AG CHF14.15 (REGD) financial statements.
Like other stocks, 0QLQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade YPSOMED HOLDING AG CHF14.15 (REGD) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So YPSOMED HOLDING AG CHF14.15 (REGD) technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating YPSOMED HOLDING AG CHF14.15 (REGD) stock shows the sell signal. See more of YPSOMED HOLDING AG CHF14.15 (REGD) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.